1. Home
  2. Vol 28, No 12 (2024)
  3. Yao

Effects of transurethral 0bipolar plasma prostatectomy on urodynamics and sexual function in patients with prostatic hyperplasia

Xiuju Yao(1), Qiuping Den(2), Guangquan L(3), Yuanbiao Guo(4),


(1) Department of Medical Laboratory, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China. Department of Clinical Laboratory, 363 Hospital, Chengdu, Sichuan 610016, China
(2) Department of Medical Laboratory, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China. Department of Clinical Laboratory, Maternity and Children’s Health Care Hospital of Jinjiang District, Chengdu, Sichuan 610016, China
(3) Department of Clinical Laboratory, 363 Hospital, Chengdu, Sichuan 610016, China
(4) Department of Medical Laboratory, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China. Medical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Third People’s Hospital of Chengdu, Chengdu, 610031, China
Corresponding Author

Abstract


This was an original article, and the objective of this study was to investigate the effects of bipolar transurethral plasma kinetic prostatectomy (TUPKP) on urodynamics and sexual function in benign prostatic hyperplasia (BPH) patients. One hundred and four BPH patients were divided into a control group and an intervention group. The control group received transurethral resection of prostate, while the intervention group received TUKEP. Relative to the control group, the intervention group presented less intraoperative blood loss and shorter bladder irrigation time, catheter retention time, and shorter hospital stay. Three months after surgery, the improvements of maximum urine flow rate (Qmax), pressure-flow rate (A-G) and residual urine volume (RV) in intervention group were more obvious than control group. One month after surgery, relative to control group, the intervention group had lower C-reactive protein (CRP), epinephrine (E) along with cortisol (Cor), cyclo-oxygenase 2 (COX-2) and vascular endothelial growth factor (VEGF) levels. On day 7 after surgery, PSA, EGF, and PGE2 levels in the intervention group were lower when compared to the control group. We conclude that TUKEP can diminish intraoperative blood loss, promote postoperative recovery, improve postoperative urodynamics and sexual function, and improve prognosis of BPH patients.

References


Geavlete B, Stanescu F, Iacoboaie C and Geavlete P. Bipolar

plasma enucleation of the prostate vs open

prostatectomy in large benign prostatic hyperplasia

cases - a medium term, prospective, randomized

comparison. BJU Int. 2013; 111(5):793-803.

Wei Z, Tao Y, Gu M, Liu C, Chen Q, Cai Z, Chen Y and

Wang Z. Plasma Kinetic Enucleation vs Holmium

Laser Enucleation for Treating Benign Prostatic

Hyperplasia: A Randomized Controlled Trial with a 3-

Year Follow-Up. J Endourol. 2021; 35(10):1533-

Gan Y, Deng L, He Q, Li C, He L and Long Z. Immediate

Transurethral Plasma Kinetic Enucleation of the

Prostate Gland for Treatment of Benign Prostatic

Hyperplasia-Associated Massive Hemorrhage: A

Single-Center Experience. Front Surg. 2021;

:810175.

Zeng XT, Li S, Gong K, Guo ZZ, Liu TZ, He DL and Wang

XH. [Evidence-based evaluation of recent clinical

practice guidelines for the diagnosis and treatment of

benign prostatic hyperplasia]. Zhonghua Yi Xue Za

Zhi. 2017; 97(22):1683-1687.

Silang J, Cai Z, Wang J, Gazang C, Zheng L, Gu Y, Luo F,

Zhang B, Fan Y and Wang F. Reliability and validity

of the Tibetan version of the International Prostate

Symptom Score. World J Urol. 2023; 41(5):1389-

Yang J, Song H, Zhan H, Ding M, Luan T, Chen J, Wei H and

Wang J. The influence of preoperative urodynamic

parameters on clinical results in patients with benign

prostatic hyperplasia after transurethral resection of

the prostate. World J Urol. 2023; 41(12):3679-3685.

van Kollenburg RAA, de Bruin DM and Wijkstra H.

Validation of the Electronic Version of the

International Index of Erectile Function (IIEF-5 and

IIEF-15): A Crossover Study. J Med Internet Res.

; 21(7):e13490.

Firoozi D, Masoumi SJ, Mohammad-Kazem Hosseini Asl S,

Labbe A, Razeghian-Jahromi I, Fararouei M,

Lankarani KB and Dara M. Effects of short-chain fatty

acid-butyrate supplementation on expression of

circadian-clock genes, sleep quality, and

inflammation in patients with active ulcerative colitis:

a double-blind randomized controlled trial. Lipids

Health Dis. 2024; 23(1):216.

Meng Q, Li J, Li M and Qiu R. Evaluation of efficacy and

safety of improved transurethral plasma kinetic

enucleation of the prostate in high-risk patients with

benign prostatic hyperplasia and coronary artery

disease. J Int Med Res. 2021;

(11):3000605211060890.

Lombardo R, Zarraonandia Andraca A, Plaza Alonso C,

González-Dacal JA, Rodríguez Núñez H, Barreiro

Mallo A, Gentile BC, Tema G, Albanesi L, Mavilla L,

Baldassarri V, De Nunzio C, Tubaro A, Ruibal Moldes

M and Giulianelli R. Laparoscopic simple

prostatectomy vs bipolar plasma enucleation of the

prostate in large benign prostatic hyperplasia: a twocenter 3-year comparison. World J Urol. 2021;

(7):2613-2619.

Liu C, Zheng S, Li H and Xu K. Transurethral enucleation

and resection of prostate in patients with benign

prostatic hyperplasia by plasma kinetics. J Urol. 2010;

(6):2440-5.

Huang J, Fan Y, Wang K, Ding H, Mao D, Zhao L and Tai

S. Transurethral 1470 nm diode laser vaporization

versus plasma kinetic enucleation of the prostate for

the treatment of benign prostatic hyperplasia: A

retrospective study. Medicine (Baltimore). 2023;

(34):e35031.

Giulianelli R, Gentile BC, Mirabile G, Tema G, Albanesi L,

Tariciotti P, Rizzo G, Falavolti C, Aloisi P, Vincenti

G and Lombardo R. Bipolar plasma enucleation of the

prostate vs. open prostatectomy in large benign

prostatic hyperplasia: a single centre 3-year

comparison. Prostate Cancer Prostatic Dis. 2019;

(1):110-116.

Xie L, Mao Q, Chen H, Qin J, Zheng X, Lin Y, Wang X and

Liu B. Transurethral vapor enucleation and resection

of the prostate with plasma vaporization button

electrode for the treatment of benign prostatic

hyperplasia: a feasibility study. J Endourol. 2012;

(10):1264-6.

Mian A, Pachorek M, Sam AP, Ruel NH, Yang D, Kohler

TS and Warner JN. Predictors of Storage Symptom

Improvement After Plasma Kinetic Enucleation of the

Prostate. Urology. 2022; 160:182-186.

Bhat A, Blachman-Braun R, Herrmann TRW and Shah HN.

Are all procedures for benign prostatic hyperplasia

created equal? A systematic review on postprocedural PSA dynamics and its correlation with

relief of bladder outlet obstruction. World J Urol.

; 40(4):889-905.

Lin J, Zhou J, Xu W, Zhong X, Hong Z and Peng J.

Qianliening capsule treats benign prostatic

hyperplasia via suppression of the EGF/STAT3

signaling pathway. Exp Ther Med. 2013; 5(5):1293-

Abo-El Fetoh ME, Abdel-Fattah MM, Mohamed WR,

Ramadan LAA and Afify H. Cyclooxygenase-2

activates EGFR-ERK1/2 pathway via PGE2-mediated

ADAM-17 signaling in testosterone-induced benign

prostatic hyperplasia. Inflammopharmacology. 2023;

(1):499-516.

Inamura S, Ito H, Shinagawa T, Tsutsumiuchi M, Taga M,

Tsuchiyama K, Kobayashi M and Yokoyama O.

Serum C-reactive protein level is not associated with

prostatic inflammation but with overactive detrusor in

patients with benign prostatic hyperplasia. Neurourol

Urodyn. 2019; 38(6):1728-1736.

Yang M, Zhu X, Shen Y, He Q, Qin Y, Shao Y, Yuan L and

Ye H. GPX2 predicts recurrence-free survival and

triggers the Wnt/β-catenin/EMT pathway in prostate

cancer. PeerJ. 2022; 10:e14263.

Basha SZ, Mohamed GA, Abdel-Naim AB, Hasan A and

Abdel-Lateff A. Cucurbitacin E glucoside from

Citrullus colocynthis inhibits testosterone-induced

benign prostatic hyperplasia in mice. Drug Chem

Toxicol. 2021; 44(5):533-543.

Raafat M, Kamel AA, Shehata AH, Ahmed AF, Bayoumi

AMA, Moussa RA, Abourehab MAS, El-Daly M.

Aescin Protects against Experimental Benign

Prostatic Hyperplasia and Preserves Prostate

Histomorphology in Rats via Suppression of

Inflammatory Cytokines and COX-2. Pharmaceuticals

(Basel). 2022; 15(2)

Trujillo-Rojas L, Fernández-Novell JM, Blanco-Prieto O,

Rigau T, Rivera Del Álamo MM and Rodríguez-Gil

JE. The onset of age-related benign prostatic

hyperplasia is concomitant with increased serum and

prostatic expression of VEGF in rats: Potential role of

VEGF as a marker for early prostatic alterations.

Theriogenology. 2022; 183:69-78.

Montiel-Jarquín Á J, Gutiérrez-Quiroz CT, Pérez-Vázquez

AL, Ortiz-Agustín JJ, García-Galicia A and LoríaCastellanos J. Quality of life and erectile dysfunction

in patients with benign prostatic hyperplasia. Cir Cir.

; 89(2):218-222.

Xing N, Guo Y, Yang F, Tian L, Zhang J, Yan Y, Kang N,

Xin Z and Niu Y. Laparoscopic simple prostatectomy

with prostatic urethra preservation for benign prostatic

hyperplasia. Transl Androl Urol. 2012; 1(1):9-13.

Wang XY, Zong HT andZhang Y. Efficacy and safety of

prostate artery embolization on lower urinary tract

symptoms related to benign prostatic hyperplasia: a

systematic review and meta-analysis. Clin Interv

Aging. 2016; 11:1609-1622.


Full Text: PDF

Article Metrics

Abstract View : 688 times
PDF Download : 237 times

Refbacks

  • There are currently no refbacks.